with bovine type II collagen (CII) emulsified in Freund's complete adjuvant (CFA). Initially, there is a preclinical period of disease development in which T and B cell autoreactivity toward CII is generated without overt signs of arthritis. With time, this results in a proliferative synovitis that is first clinically observed 2-3 days following the second immunization, featuring polymorphonuclear and mononuclear cellular infiltrates, formation of pannus, degradation of cartilage, fibrosis, and bone erosion (9) . The model depends not only on generation of T and B cell reactivity to CII, but also on complement activation and generation of the systemic cytokines interleukin-1b (IL1b), IL-6, IL-17, interferon-c (IFNc), and tumor necrosis factor (TNF); the absence or inhibition of any of these factors significantly attenuates disease development (10) (11) (12) (13) .
Recently, others have described intestinal dysbiosis at the terminal time point of this model in mice that developed disease compared to those that were immunized but did not develop observable joint swelling (14) . Transfer of fecal material from arthritic mice but not from nonarthritic, immunized mice into germfree mice followed by CII immunization resulted in disease induction (14) . However, questions from that study remain unanswered regarding microbial changes over time and whether there is a time-dependent role for microbiota in pathogenesis. Furthermore, that study did not address the mucosal or systemic effects of the microbial changes or the possible mechanism(s) by which microbiota modulate susceptibility to CIA.
Given the outstanding questions regarding the influence of dysbiosis at various stages during the development of inflammatory arthritis, we hypothesized that intestinal microbial communities would be dynamic during the course of CIA and would demonstrate multiple phases of dysbiosis. In turn, dysbiosis would be expected to modulate local intestinal mucosal immune factors that promote systemic inflammation, autoantibody generation, and disease severity. Furthermore, we hypothesized that microbiota would affect disease development differently at discrete time points in the development of disease. Using the CIA model, we assessed microbial changes in the intestine throughout the course of disease and identified the critical time points at which dysbiosis modulated disease activity. We characterize the mucosal and systemic immune responses that correlate with dysbiosis, and we propose that microbiota alter disease in CIA through modulation of cytokines and autoantibody production.
MATERIALS AND METHODS
CIA. Six-week-old male DBA/1J mice (The Jackson Laboratory) were injected intradermally with 200 lg bovine CII (Chondrex) emulsified in 50 ll CFA (Sigma) on days 0 and 21. As controls, a subset of mice was immunized with only 50 ll CFA on days 0 and 21. Disease severity was measured as a mean clinical score for each of the animal's 4 paws, where 0 = normal, 1 = erythema, 2 = swelling, and 3 = ankylosis. At the specified time points, feces, serum, and tissue samples were harvested from mice. All animal experiments were approved by the University of Colorado School of Medicine Institutional Animal Care and Use Committee.
Collagen antibody-induced arthritis (CAIA). Sixweek-old male DBA/1J mice were given antibiotic or control drinking water for 1 week prior to and throughout the study. Mice were injected intraperitoneally (IP) with 1.5 mg of 5-clone anti-CII antibody cocktail (Chondrex) on day 0. On day 3, 50 lg of lipopolysaccharide was injected IP. Arthritis scoring was done every day starting on day 4 through day 10. Disease severity was assessed as described above for CIA.
Microbiome analysis. Fresh fecal samples were collected at 7-day intervals throughout the course of CIA. Total genomic DNA was extracted using an UltraPure Fecal DNA kit (Mo Bio) according to the manufacturer's protocol. Harvested DNA was amplified by polymerase chain reaction (PCR) with broad-range bacterial primers targeting the 16S ribosomal RNA (rRNA) gene hypervariable regions V1 and V2 and pooled amplicons subjected to Illumina MiSeq sequencing, as previously described (15) (16) (17) . Assembled sequences were aligned and classified with SINA (1.3.0-r23838) (18) using the 418,497 bacterial sequences in Silva 115NR99 (19) as reference configured to yield the Silva taxonomy. Operational taxonomic units (OTUs) were produced by clustering sequences with identical taxonomic assignments. OTUs with >0.01% abundance in any sample and observed in >5% of the samples were included in further analyses. Analyses of OTU relative abundance and biodiversity were conducted using Explicet software (20) . All samples had a Good's coverage index >99%, indicating excellent depth of sequencing coverage.
Fluorescein isothiocyanate (FITC)-labeled dextran flux. Mice were orally gavaged with 0.6 mg/kg body weight FITClabeled 4-kd dextran (Sigma), and serum was collected 4 hours later. The amount of fluorescence was measured with a fluorometer (Promega) at 485/530 nm. A standard curve was generated to calculate the amount of dextran that was present in the sera.
Histopathology. Whole colon tissue was harvested from mice, flushed with 19 phosphate buffered saline (PBS), dissected longitudinally, and pinned in wax for fixation in formaldehyde overnight. Tissues were then embedded in paraffin. Sections of 5 lm were cut from paraffin-embedded tissues and stained with hematoxylin and eosin. Four high-power fields of well-oriented colon tissue per mouse were analyzed at 409 magnification for quantification of inflammatory cells in the lamina propria, numbers of mitotic figures, and length of crypts.
Cytokine assay. A multianalyte enzyme-linked immunosorbent assay (ELISA; Meso Scale Diagnostics) was used to measure the levels of IFNc (lower limit of detection 0.04 pg/ml), IL-12p70 (lower limit of detection 9.95 pg/ml), IL-1b (lower limit of detection 0.11 pg/ml), IL-6 (lower limit of detection 0.61 pg/ml), IL-10 (lower limit of detection 0.95 pg/ml), IL-22 (lower limit of detection 1.2 pg/ml), IL-23 (lower limit of detection 4.9 pg/ml), IL-17A (lower limit of detection 0.3 pg/ml), and TNF (lower limit of detection 0.13 pg/ml) in tissue lysates and serum, following the manufacturer's instructions. In tissues, cytokines were normalized to total protein content of the tissue lysate, which was determined using a Pierce BCA Protein Assay kit (ThermoFisher Scientific).
Anti-CII ELISA. Ninety-six-well plates (Costar; Corning) were coated overnight at 4°C with 5 lg/ml ELISA-grade mouse CII (Chondrex). The plates were then washed and blocked with 0.01% bovine serum albumin (BSA) in 19 PBS for 4 hours at 4°C. Plates were washed again 3 times. Serum samples were diluted 1:10,000 in 19 PBS. Samples were added to wells and incubated overnight at 4°C. The plates were then washed, and horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Jackson ImmunoResearch) or goat anti-mouse IgG1, IgG2a, or IgG2b (all from Invitrogen) diluted 1:1,000 in 19 PBS was added for 4 hours at 4°C. Following washing, 19 tetramethylbenzidine (TMB) ELISA substrate solution (eBioscience) was added to wells for 30 minutes at room temperature. The reaction was then stopped with 2N H 2 SO 4 and read at 450 nm. Pooled serum from several mice with severe CIA was used to generate a standard curve in which the top standard was diluted 1:2,000 and considered 250 units/ml (21) .
Antibiotic treatment. Ampicillin (1 gm/liter), neomycin (1 gm/liter), vancomycin (0.5 gm/liter), metronidazole (0.5 gm/liter) (all from Sigma), and sugar-sweetened grape Kool-Aid (20 gm/liter) (Kraft Foods) were given in drinking water to mice starting on day À7 (before immunization on day 0) and stopped on day 0 for the short course or continued throughout the study for the early long course. For the late course of antibiotics, mice were provided the antibiotic drinking water beginning on day 21 through the end of the study. Controls received 20 gm/liter Kool-Aid in drinking water.
Quantitative PCR (qPCR). Bacterial DNA from feces was extracted as described for microbiome analysis. To determine total bacterial load, qPCR reactions consisted of 1 ll bacterial DNA or complementary DNA, 0.6 lM each forward and reverse primers, 19 SYBR Green PCR Master Mix (Applied Biosystems), and water for a total volume of 17 ll. Samples were denatured at 95°C for 2 minutes, cycled 40 times through 95°C for 20 seconds, 58°C for 20 seconds, and 72°C for 30 seconds, and then denaturation curves were determined from 58°C through 95°C. All qPCR assays were conducted in an Applied Biosystems 7500 real-time PCR system. Bacterial 16S universal primers 5 0 -TCCTACGG-GAGGCAGCAGT-3 0 (forward) and 5 0 -GGACTACCAGGG-TATCTAATCCTGTT-3 0 (reverse) (22) were used for fecal microbial DNA quantification. Both control water-treated and antibiotic-treated mice were assayed simultaneously within each reaction for fecal microbial DNA using a bacterial DNA standard curve for calculation of bacteria concentration in ng/ll. Concentrations were normalized to fecal weight. In each reaction, individual samples were compared to the mean concentration of bacteria in control water-treated mice to report the percent of control microbiota.
C3 activation ELISA. Ninety-six-well plates were coated overnight at 4°C with 5 lg/ml ELISA-grade mouse CII. The ELISA plates were then washed and blocked with 0.01% BSA in 19 PBS for 4 hours at 4°C. The ELISA plates were washed 3 times. Serum samples were diluted 1:10,000 in 19 PBS. Samples were added to wells and incubated overnight at 4°C. Next day, the wells were washed 5 times with 19 PBS, then incubated with 15% normal mouse serum diluted in Dulbecco's PBS plus 0.9 mM CaCl 2 plus 0.5 mM MgCl 2 for 30 minutes at 37°C. The plates were then washed 5 times with 19 PBS and incubated with HRPconjugated goat IgG to mouse C3 (Cappel/MP Biomedicals) in 1:2,500 dilution for 1 hour at room temperature with rocker shaking. The plates were washed with 19 PBS and developed with 19 TMB ELISA substrate solution for 10 minutes. The reaction was then stopped with H 2 SO 4 and read at 450 nm.
Glycosylation studies. Serum total IgG was purified by using Pierce Protein G Agarose (ThermoFisher Scientific) following the manufacturer's instructions. To concentrate the eluted total IgGs, 3-kd Ultra-0.5 ml centrifugal filter units (Amicon) were used. Total N-linked glycan was released from glycoproteins using PNGase F (New England Biolabs) according to the manufacturer's instructions. Deglycosylation reactions were carried out at 37°C overnight to ensure effective release of glycans. Glycans were purified from the reaction using GlykoClean G Cartridges (Prozyme), dried, and fluorescence labeled with 2-aminobenzamide (Sigma-Aldrich). Labeled glycans were cleaned with GlykoClean S-plus Cartridges (Prozyme), dried, and subjected to highperformance liquid chromatography analysis. Glycan samples were dissolved in 100 mM ammonium formate (pH 4.5) and separated using an Agilent 1260 Infinity Quaternary LC system outfitted with a 2.1 9 150 mm AdvanceBio Glycan Mapping column with 2.7 lm superficially porous particles and a fluorescence detector. Resulting peaks were analyzed in OpenLAB software (Agilent) and assigned glycoforms by comparing peaks of commercially available human IgG N-linked glycan library.
Statistical analysis. Microbiome data were analyzed using Explicet (version 2.10.5) (20) and R statistical software, including the Vegan package (23) . Tests of overall community composition used a permutational multivariate analysis of variance (PERMANOVA) test of Morisita-Horn dissimilarity scores, with P values estimated through 1,000,000 permutations. Alpha diversity indices were estimated through 1,000 resamplings at the rarefaction point of 90,000 sequences. Betweengroup differences in alpha diversity were assessed by ANOVA. Both PERMANOVA and ANOVA tests included mouse identification numbers to factor out animal-to-animal variability, as might occur through cage effects. Other data were analyzed with GraphPad Prism software version 7.01; specific statistical tests for comparisons are referenced in the figure legends.
RESULTS
Microbial communities and mucosal inflammation change continuously through the course of CIA. Because dysbiosis is observed in individuals with symptomatic RA (7, 24) and in mice with clinical arthritis (14, 25) , we queried when dysbiosis developed during the CIA disease process. CIA was induced by immunization of 6-week-old male DBA/1J mice with CII in CFA on days 0 and 21, with arthritis first observed on days 23 and 24. We collected fecal samples on day 0 and every 7 days during the course of CIA until the end of the study on day 35. DNA from fecal pellets was isolated and subjected to broad-range bacterial 16S rRNA gene amplification (hypervariable regions V1 and V2) and high-throughput sequencing.
Compared to fecal samples collected on day 0 ( Figure 1A ), appreciable differences in overall microbiota composition were observed in fecal samples collected on day 14 (P = 0.032 by PERMANOVA) and day 21 (P = 0.0063 by PERMANOVA). Significant differences also were observed between day 7 and day 14 1222 JUBAIR ET AL (P = 0.040 by PERMANOVA) and between day 7 and day 21 (P = 0.010 by PERMANOVA). Although microbiota composition on day 35 did not differ significantly from that at previous time points, the smaller number of animals sampled at this time point (n = 6, compared to n = 11 for all other time points) likely limited statistical power in the PERMANOVA tests. Nevertheless, 2 measures of microbial biodiversity, evenness and Shannon complexity, progressively declined over the course of CIA and were significantly lower on day 35 than on days 0 and 7 ( Figure 1B ). Comparison of bacterial families over time revealed that Lactobacillaceae significantly expanded while S24-7 was significantly reduced on days 14 and 21, and Lachnospiraceae was significantly increased on day 35 compared to baseline ( Figure 1C ). It is difficult to determine if the changes in microbial communities observed in mice with CIA are due solely to an innate immune response generated by the adjuvant, as the microbiome profile of CFA-immunized mice also changed dynamically over time but in a different pattern compared to those with CIA (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://online library.wiley.com/doi/10.1002/art.40490/abstract).
Thus, significant changes in the composition and diversity of the fecal microbiota appeared to occur during the early, preclinical stages of CIA prior to arthritis being observed.
We next examined whether the observed dysbiosis was accompanied by intestinal mucosal changes during the development of CIA. To address this, we first evaluated intestinal barrier integrity, as assessed by permeation of FITC-labeled dextran, a non-digestible sugar that Figure 1 . Microbial dysbiosis occurs early during development of collagen-induced arthritis. Six-week-old male DBA/1J mice were immunized with type II collagen in Freund's complete adjuvant on days 0 and 21. Fecal pellets were collected from mice every 7 days from day 0 through day 21 and on day 35 after the initial immunization. Fecal bacterial DNA was sequenced for 16S ribosomal RNA (rRNA) and analyzed (n = 11 mice for days 0-21 and n = 6 mice for day 35). Data are from 2 independent experiments. A, The percent abundance of the families with the greatest numbers of operational taxonomic units (OTUs) was compared across time points. Color legend is Phylum: Family. Phyla include Firmicutes (Firm.), Bacteroidetes (Bact.), and Deferribacteres (Def.). Differences in the overall composition of microbial communities were determined by permutational multivariate analysis of variance. * = P < 0.05; ** = P < 0.01. B, Alpha diversity measures for richness (Chao1), evenness (Shannon H/Hmax [the maximum possible Shannon H if all OTUs were evenly distributed]), and complexity (Shannon H) across time points are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th percentiles. * = P < 0.05; ** = P < 0.01; • = P < 0.001, by analysis of variance. C, Statistically significant changes in family-level OTU relative abundance were determined by Kruskal-Wallis test with Dunn's post hoc test. Values are the mean AE SEM. *** = P < 0.001; **** = P < 0.0001.
MODULATION OF INFLAMMATORY ARTHRITIS BY MICROBIOTA
paracellularly permeates an impaired intestinal barrier and can be detected in serum. During the development of CIA, elevated dextran levels were first detected in the serum on day 14 and further increased significantly on day 35 in mice with CIA but not in CFA-treated controls (Figure 2A) , suggesting that intestinal barrier impairment occurred at these time points during the development of CIA.
Barrier impairment was likely caused by inflammation, as histologic analysis of colon tissue from mice with CIA on day 35 compared to that from untreated DBA/1J and CFA-treated control mice demonstrated significantly increased inflammatory cell infiltration in the lamina propria, increased crypt cell mitosis, and crypt hyperplasia ( Figures 2B-E) . Furthermore, as another indication of Figure 2 . Mucosal inflammation parallels dysbiosis during development of collagen-induced arthritis (CIA). Six-week-old male DBA/1J mice were immunized with type II collagen in Freund's complete adjuvant (CFA) on days 0 and 21. A, Barrier integrity was assessed by permeation of fluorescein isothiocyanate (FITC)-labeled dextran orally gavaged and detected in serum 4 hours later. Values are the mean AE SEM (n = 10 mice per group). *** = P < 0.001; **** = P < 0.0001 versus mice on day 0, by repeated-measures analysis of variance. B, Shown is representative histology from control DBA/1J mice, CFA-treated control mice, and mice with CIA on day 35. Arrows indicate mitotic figures that are quantified in D. Bars = 20 lm. C-E, Four highpower fields (hpf) of well-oriented colon tissue per mouse were analyzed at 409 magnification for quantification of inflammatory cells in the lamina propria (C), epithelial mitotic figures (D), and crypt length (E) (n = 3-6 mice per group). Symbols represent individual mice; bars show the mean AE SEM. * = P < 0.05 by Mann-Whitney test. F-H, Levels of interleukin-17A (IL-17A) (F), IL-22 (G), and IL-23 (H) in small intestine (SI), colon, and mesenteric lymph nodes (MLNs) were measured by enzyme-linked immunosorbent assay in DBA/1J nonimmunized control mice on day 0, CFA-treated control mice, and mice with CIA on days 14 and 35 after initial immunization (n = 3-6 mice per group). Cytokine concentrations were normalized to total protein. Values are the mean AE SEM. * = P < 0.05; ** = P < 0.01, by Kruskal-Wallis test with Dunn's post hoc test. ND = not detectable.
intestinal mucosal inflammation, cytokines in whole tissue homogenates from the small intestine, colon, and mesenteric lymph nodes (MLNs) from mice with CIA on days 14 and 35, but not from CFA-treated controls, demonstrated early significant increases in IL-17A and IL-22 and a trend toward an increase in IL-23 ( Figures 2F-H) , while the cytokines IFNc, IL-12p70, IL-1b, IL-6, IL-10, and TNF were not significantly affected in mice with CIA (see Supplementary Figure 2 , http://onlinelibrary.wiley.com/doi/10. 1002/art.40490/abstract). Taken together, these data strongly suggest a pattern of intestinal dysbiosis correlating with a Th17 pattern of mucosal inflammation that begins before arthritis is clinically observed in CIA.
Microbiota influence disease severity in CIA through modulation of mucosal and systemic cytokines and autoantibodies. To clarify the role of microbiota for the development of CIA, we used broad-spectrum antibiotics (ampicillin, metronidazole, neomycin, and vancomycin) in drinking water to deplete the microbiota. Three treatment regimens were used ( Figure 3A ). These were oral antibiotic treatment or control water starting 7 days prior to induction of CIA and continuing throughout the study (early long course); antibiotic treatment or control water for only 7 days prior to induction of CIA followed by control water (early short course); and control water from 7 days prior to induction of CIA until day 21, Figure 3 . Depletion of microbiota by administration of antibiotics (Abx) reduces severity of collagen-induced arthritis (CIA). Six-week-old male DBA/1J mice were treated with broad-spectrum antibiotics in drinking water starting 1 week before immunization with type II collagen (CII) and stopping on day 0 (early short course) or continuing until euthanasia on day 35 (early long course). Another group of mice was treated with antibiotics from day 21 through day 35 (late course). All groups were paired with control water-treated mice. All antibiotic-and control water-treated groups underwent immunization with CII in Freund's complete adjuvant on days 0 and 21. A, Diagram of experimental treatments is shown. B, Arthritis scores were assessed every other day starting after day 21 (n = 6-14 mice per group). Values are the mean AE SEM. * = P < 0.05; ** = P < 0.01; **** = P < 0.0001, by two-way analysis of variance (ANOVA) with Bonferroni adjustment for multiple comparisons. C, Serum anti-CII IgG was measured by enzyme-linked immunosorbent assay (n = 6-11 mice per group). Values are the mean AE SEM. * = P < 0.05; **** = P < 0.0001, by two-way ANOVA with Bonferroni adjustment for multiple comparisons. followed by antibiotic treatment or control water until the end of the study (late course; days [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . To confirm microbial depletion in antibiotic-treated mice, the microbial load in fecal samples was measured by qPCR using a universal 16S rRNA primer set (22) . The bacterial concentration in each mouse sample was compared to the mean bacterial concentration in the control group, and samples that were not below the 10% confidence interval for the median normalized bacterial abundance in control water-treated mice were excluded from further analyses (see Supplementary Figure 3A , http://onlinelibrary.wiley. com/doi/10.1002/art.40490/abstract). No differences in the total microbial abundance of both early antibiotic treatment courses (early short versus early long) on day 35 were detected; thus, the 2 treatment groups were combined in our analyses.
Following immunization of antibiotic-treated and control mice on days 0 and 21, mice were assessed for the severity of arthritis every other day until day 35, at which time they were euthanized. Mice given early antibiotic treatment (early short course or early long course) (Figure 3 ; also see Supplementary Figure 3B , http://onlinelibrary. wiley.com/doi/10.1002/art.40490/abstract) demonstrated a 40% reduction in the severity of arthritis on day 35, while, surprisingly, mice treated with antibiotics after the second immunization (late course) developed only a slight, transient arthritis that was >95% reduced in severity ( Figure 3B ). The prevalence of arthritis on day 35 with early antibiotic treatment remained 100%, the same as that in mice with CIA receiving control water; however, the prevalence of arthritis was significantly reduced to~50% (P < 0.0001 by log rank test) with late antibiotic treatment compared to control treatment (see Supplementary Figure 4A , http://onlinelibra ry.wiley.com/doi/10.1002/art.40490/abstract).
Supporting the finding of reduced disease severity, the levels of 4 inflammatory cytokines important for the development of CIA (IFNc, IL-1b, IL-6, and TNF) (26, 27) were significantly decreased in both early and late antibiotic-treated mice with CIA ( Supplementary Figure 4D) , with a more profound reduction in the late antibiotic-treated mice. The development of serum anti-CII IgG antibodies was significantly delayed in mice given early antibiotics, but late antibiotic treatment mildly reduced the development of these antibodies, although not significantly ( Figure 3C ). Intriguingly, while arthritis scores correlated positively with microbial abundance in both the early and late antibiotic-treated groups (Supplementary Figure 4B ), serum CII autoantibody levels only correlated with early antibiotic treatment and not with late antibiotic treatment (Supplementary Figure 4C) .
Because we observed day 14 as the earliest time point for dysbiosis and mucosal inflammation characterized by elevated IL-17A, IL-22, and IL-23 in our initial experiments, we measured the levels of these 3 cytokines in small intestine, colon, and MLNs of mice treated with antibiotics or control water during CIA. Levels of IL-17A and IL-22 were significantly decreased in the small intestine of mice with CIA after depleting microbiota with early antibiotic treatment, while the level of IL-23 remained unaffected ( Figure 4A ). However, on day 35, all 3 cytokines were significantly increased in the early antibiotic-treated mice compared to controls (Figure 4B) . Intriguingly, levels of IL-17A and IL-22 were significantly decreased in intestinal tissues from mice with CIA and late antibiotic treatment compared to those in mice with CIA and control treatment, while levels of IL-23 were significantly reduced in the colon and MLNs ( Figure 4C ). Thus, it appears that microbiota may have differing, time-dependent effects on the development of both mucosal and systemic immune responses that result in CIA. Levels of IL-17A, IL-22, and IL-23 were unchanged at the draining inguinal lymph nodes for the CIA immunization site in control-and antibiotic-treated mice (see Supplementary Figure 5 , http://onlinelibrary. wiley.com/doi/10.1002/art.40490/abstract), which suggests that the Th17-derived cytokines originate in the intestinal tissues and associated MLNs rather than at the site of immunization.
To determine whether antibiotic treatment may have antiinflammatory properties during the effector phase of arthritis, we used the CAIA model. In this model, arthritis is induced in DBA/1J mice by transferring a cocktail of 5 murine monoclonal antibodies to CII, bypassing the need to develop an adaptive immune response. DBA/1J mice were treated with antibiotics or control drinking water for 1 week prior to anti-CII antibody transfer and throughout the study. Arthritis severity was unaffected by treatment of mice with antibiotics (see Supplementary Figure 6 , http://onlinelibrary.wiley. com/doi/10.1002/art.40490/abstract), demonstrating that antibiotics themselves did not modulate inflammation but rather that microbiota modulated the developing immune responses that lead to arthritis. This conclusion is further supported by our finding that mice that did not have microbial depletion while receiving antibiotics developed CIA disease severity similar to that in controls (see Supplementary Figure 3C , http://onlinelibrary. wiley.com/doi/10.1002/art.40490/abstract).
Microbial depletion impairs autoantibody function in CIA without affecting IgG isotypes. One striking feature of our data was the profound reduction in arthritis incidence and severity when microbiota were depleted beginning on day 21 after the induction of CIA, particularly since total IgG anti-CII antibodies 1226 JUBAIR ET AL were only slightly reduced ( Figure 3C ). To explore the potential mechanism for protection from disease, we assessed the functionality of CII autoantibodies in the serum from the mice by examining their ability to activate C3. Strikingly, anti-CII antibodies from the serum of mice treated with antibiotics late in the course of Values are the mean AE SEM (n = 6-11 mice per group). * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001, by Kruskal-Wallis test with Dunn's post hoc test. NS = not significant.
CIA failed to activate C3 compared to those from serum of control-treated or early antibiotic-treated mice with CIA (Figures 5A and B ; also see Supplementary Figure 7 , http://onlinelibrary.wiley.com/doi/10.1002/ art.40490/abstract). While these findings may have been due in part to a decrease in IgG2b isotype anti-CII antibodies in the late antibiotic treatment group, the same trends in CII autoantibodies were observed in the early antibiotic treatment group (see Supplementary  Figure 8 , http://onlinelibrary.wiley.com/doi/10.1002/art. 40490/abstract), which did not demonstrate reduced complement activity.
Since autoantibody glycosylation could significantly impact the immune reactivity and complementdependent cytotoxicity at the effector phase, we measured and analyzed glycosylation patterns of total serum IgG in mice with CIA treated with control water, early antibiotics, and late antibiotics. While control water-treated and early antibiotic-treated mice with CIA showed similar glycosylation profiles, mice with CIA that were treated with antibiotics late on day 21 demonstrated lower galactose levels ( Figures 5C-E) . Thus, we conclude that the antibiotic-induced alteration of microbiota on day 21 after induction of disease led to significant glycosylation changes accompanied by reduction in anti-CII antibody activation of complement.
DISCUSSION
There is an increasing appreciation of the role of the microbial-mucosal imbalance in the development of autoimmune diseases (7, 8, (28) (29) (30) . Using the Figure 5 . Microbiota alter the ability of serum autoantibodies to activate complement. Activation of the classical pathway of complement on day 35 by serum anti-type II collagen antibodies from control-treated mice with collagen-induced arthritis (CIA) or mice with CIA treated with antibiotics (Abx) was assessed by a modified enzyme-linked immunosorbent assay described in Materials and Methods. A, Levels of C3 deposition induced by anti-type II collagen antibodies in control-treated mice with CIA and mice with CIA treated with early antibiotics. B, Levels of C3 deposition induced by anti-type II collagen antibodies in control-treated mice with CIA and mice with CIA treated with late antibiotics. C-E, Glycosylation profiles in sera on day 35 from mice with CIA treated with early antibiotics, control-treated mice with CIA, and mice with CIA treated with late antibiotics. Agalactosylated (G0) (C), galactose (Gal) (D), and sialic acid (Sia) (E) content in purified serum immunoglobulins was quantified by high-performance liquid chromatography. Symbols represent individual mice; bars show the mean AE SEM (n = 6-11 mice per group). * = P < 0.05 by Student's 2-tailed t-test. NS = not significant.
CIA murine model, we investigated the importance of microbiota in developing inflammatory arthritis. Our results suggest that significant shifts in the composition and diversity of microbial communities occurred during the first 21 days of the CIA model. In parallel, mucosal barrier impairment was observed with an initial insult at day 14 that stabilized through day 21 but worsened by day 35. Early after induction of CIA by day 14, we observed a reduction in the abundance of the Bacteroidetes class S24-7 and an increase in Lactobacillaceae; however, by day 35 Lactobacillaceae and S24-7 returned to day 0-7 levels, while Lachnospiraceae significantly increased in abundance. These are consistent with a previous study showing the same trends in Lactobacillaceae and Lachnospiraceae in mice with advanced CIA compared to nonimmunized mice (14) .
Mucosal inflammation in the intestine as determined by colon histology and elevation of the tissue cytokines IL-17A and IL-22 paralleled dysbiosis during the development of CIA. Intriguingly, despite robust inflammatory responses that are elicited by CFA, the significant changes in intestinal microbial communities in these mice did not result in the generation of local Th17 cytokine responses, suggesting that the developing autoimmune response to CII is an element of the mucosal changes. We found that mucosal levels of IL-17A and IL-22, particularly in the small intestine, were significantly increased on day 14 of CIA when the abundance of S24-7 was low and the abundance of Lactobacillaceae was increased. Levels of both cytokines then decreased by day 35 of CIA to those near day 0, just as the abundance of S24-7 and Lactobacillaceae returned to that near day 0.
These 2 bacterial groups, S24-7 and Lactobacillaceae, are well-described inhabitants of the gastrointestinal tract of humans and animals (31, 32) . S24-7 is an IgA-coated, normal commensal of the gut in humans and murine models, and it is involved in carbohydrate fermentation and utilization (32) (33) (34) , while Lactobacillaceae are thought to have a regulatory effect on host immunity (35) . For example, Lactobacillus salivarius and Lactobacillus plantarum transferred to mice prior to the induction of CIA reduced Th17 cells and increased Treg cells and resulted in reduced arthritis severity (36) . The precise mechanism by which these microbial changes during the development of CIA modulate host immunity requires further study. However, using a known oral pathogen, Sandal et al demonstrated that oral infection with Porphyromonas gingivalis could transiently expand Th17 cells in the draining cervical lymph nodes and circulation and exacerbated disease in HLA-DRB1-transgenic mice with CIA, even in those that had previously resisted development of disease (37) . Another study showed that treatment by oral gavage with Prevotella histicola attenuates CIA in HLA-DQ8-transgenic mice by increasing IL-10-producing Treg cells and reducing Th17 cells in the gut (38) . These provocative findings along with those in the K/BxN model (25) and ours presented herein suggest that specific bacteria that stimulate mucosal Th17 cells drive disease development.
Depletion of microbiota through administration of broad-spectrum antibiotics resulted in decreased disease severity, reduced autoantibody generation, and impaired Th17-derived cytokine responses. The impact of intestinal microbes in the development of inflammatory arthritis was previously proposed in the K/BxN mouse model. This is a spontaneous model of inflammatory arthritis that is due to a transgenic T cell receptor recognizing the ubiquitous autoantigen glucose-6-phosphate isomerase (GPI). The well-described pathology is similar to that in RA and begins at the age of~4 weeks; it requires Tcell help for the generation of autoreactive B cells producing anti-GPI autoantibodies (39, 40) . In a germ-free environment, mice develop delayed onset of arthritis with reduced severity. Segmented filamentous bacteria were shown to modulate autoantibodies to GPI through the development of Th17 cells and follicular helper T cells within the intestines (25, 41) . Although our study did not assess the presence of Tcell subsets in the intestines of mice with CIA, we did find increased intestinal tissue IL-17A and IL-22 (two products of Th17 cell activation), which supports the development of Th17 cells during CIA. Similarly, microbial depletion in mice with CIA through use of broad-spectrum antibiotics resulted in an initial significant decrease in IL-17A and IL-22 in intestinal tissues, suggesting a decrease in Th17 cell presence or activation. In conjunction, we observed a positive correlation between microbial abundance and the production of autoantibodies, which is consistent with the K/ BxN studies.
It remains unknown whether commensal bacteria are necessary for the development of CIA. Use of broadspectrum antibiotic in our study allowed depletion of the microbiota but not complete removal of all bacteria, as previously noted by others (42) . Depleting microbiota early either with 1 week of antibiotic administration or with continuous administration throughout the study resulted in the same effect on all disease assessments. This observation excludes the possibility that our results are solely due to direct antibiotic modulation of mucosal immunity, confirmed by our CAIA studies in which antibiotic treatment did not affect disease severity. To avoid the confounding effects of antibiotics and residual bacteria, germ-free studies will be critical in establishing direct effects of specific bacteria in modulating immune responses and disease development in CIA.
In the setting of a reduced microbial load, we note significantly decreased CIA disease prevalence and severity. Most surprising, though, was our finding that the reduction in microbial burden at the time of the second, booster immunization had a more profound effect on disease severity. Our further investigations showed that although total and IgG2b subclass anti-CII antibodies were only mildly reduced in antibiotictreated mice, these antibodies were significantly impaired in their ability to activate complement.
Autoantibody function has been linked to decreased glycosylation of the Fc segment in CIA (43, 44) and in individuals with RA (45, 46) . An important effect of glycosylation of the Fc portion of autoantibodies is the modulation of complement activation (47) , which is required for CIA (21, 43, 48) . In our study, mice treated Figure 6 . Proposed mechanism for microbial modulation of collagen-induced arthritis (CIA). During the early, preclinical phase of CIA, changes in the intestinal microbiome occur, which are associated with a more permeable barrier and mucosal inflammation. Mucosal inflammation is characterized by Th17 responses, as reflected by high levels of interleukin-17A (IL-17A) and IL-22 in tissue, and downstream activation of B cells (B) and mucosal autoantibody production. Circulation of mucosa-generated Th17 and B cells leads to systemic autoimmunity. Microbiota also influence autoimmune arthritis later in the disease course, by promoting complement (C 0 ) activation by autoantibodies, possibly via altered glycosylation (*). M/ = macrophage; Tfh = follicular helper Tcell; GC = germinal center; TNF = tumor necrosis factor; IFNc = interferon-c; LNs = lymph nodes.
with late antibiotics exhibited a distinctive glycosylation profile, with lower galactose levels. Importantly, terminal galactose residues increase antibody binding to C1q, resulting in C3b deposition and more proinflammatory IgG effector functions (44, 47) . Another recent study linked the activity of pathogenic IgG in both the CIA and K/BxN models to IL-23-regulated Fc glycosylation, in particular sialylation (49) . Although in our studies levels of IL-23 in the MLNs of mice in the late antibiotictreated group were reduced during late antibiotic treatment, we did not observe an alteration in the sialylation of immunoglobulins from these mice. Clearly, additional studies are needed to solidify the role of the microbiota in driving CIA via modulation of antibody glycosylation, but our data together with those of others (25, 50, 51) support the mechanism proposed in Figure 6 .
In our studies, we examined how both the microbiota and mucosal immune response change over the course of CIA development, which has not been the focus of previous studies that link microbiota with the development of autoimmune arthritis (14, 25, 50) . We were intrigued to observe that modification of the microbiota through administration of broad-spectrum antibiotics at different time points during disease resulted in different patterns of mucosal and systemic immune responses. Depletion of the microbiota prior to the induction of CIA resulted in an initial decrease in mucosal IL-17A and IL-22 levels and anti-CII autoantibodies by day 14; however, by day 35, mucosal levels of IL-17A, IL-22, and IL-23 were significantly increased compared to those in mice with CIA receiving control water, and anti-CII autoantibodies appeared to be trending toward similar levels between the 2 groups. Although the antibiotic-treated mice had >50% reduction in the total microbial burden compared to controls, shifts in specific bacterial OTUs during the course of CIA with antibiotics may explain this later "catching up" of the Th17 response.
Similarly, when mice with CIA were given antibiotics after the induction of disease, we found significantly reduced levels of mucosal IL-17A and IL-22 as well as IL-23 in the MLNs that we propose are linked to reduced autoantibody effector function. Again, this may be related to shifts in specific bacterial taxa without an effect of the overall microbial abundance. Such shifts occurring after a local Th17 response has developed, on day 14 as suggested by our studies, could modify the local and systemic immune milieu much more differently from the way that microbial shifts would affect immunity prior to the Th17 response, on day 0. Thus, we suggest that there are differing, time-dependent effects of the microbiota on the developing immune responses during CIA.
In summary, we characterize the intestinal microbiome and mucosal changes that occur during CIA. We demonstrate that in the absence of an intact microbiota, mice with CIA fail to develop robust disease. We propose that microbial dysbiosis in the preclinical phase of CIA is associated with significant mucosal changes. These changes provoke a mucosal Th17 immune response, educate mucosal lymphoid tissues to produce autoantibodies, and modulate the effector functions of autoantibodies. Autoreactive B cells that develop at mucosal surfaces expand, circulate, and result in systemic autoimmunity ( Figure 6 ). While additional studies are needed to identify causative bacteria more specifically and validate our proposed mechanism, targeting the microbiota during the preclinical phase of RA may have potential for disease prevention.
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